CD44 and acute myeloid leukemia: The use of H90, an anti-CD44 mAb, broke the interaction between CD44 and HA and caused a marked reduction of the leukemic burden in non-obese diabetic/severe combined immunodeficiency (NOD-SCID) mice transplanted with primary AML cells.